Insulin-sensitizing therapies such as metformin may exert a threefold effect by lowering the risk of diabetes progression, reducing insulin-mediated ovarian androgen synthesis, and decreasing IGF-1 levels (46, 47). This evidence concerns the gene INS and diabetes mellitus.